Business Description
Founded in 2010 and headquartered in Basel, Switzerland, BeOne Medicines AG is a global cancer medicine company that discovers and develops treatments for patients across the United States, China, Europe, and beyond. Its portfolio of approved products includes BRUKINSA for blood cancers, TEVIMBRA for solid tumors and blood cancers, and several other therapies targeting conditions ranging from breast cancer to rare immune disorders. The company also has a broad pipeline of experimental treatments at various stages of clinical testing, covering a wide range of cancer targets and treatment approaches. BeOne Medicines works alongside partners such as Amgen, Bristol Myers Squibb, and Novartis to advance its mission, and was previously known as BeiGene Ltd. before changing its name in May 2025.
